Stockholm, Sweden, November 10, 2023. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX), today announced that the Company, through its wholly-owned subsidiary Rare Thyroid Therapeutics International AB, has entered into an exclusive license agreement with Fujimoto Pharmaceutical Corporation (“Fujimoto”) to develop and commercialize Emcitate (tiratricol), for the treatment of MCT8 deficiency, in Japan. Under the terms of the agreement Egetis grants Fujimoto exclusive development and commercialization rights to Emcitate for the treatment of MCT8 deficiency in Japan. Fujimoto will pay upfront, development, and regulatory milestones amounting to JPY 600 million (approximately SEK 45 million). Egetis will supply Fujimoto with product in semi-finished form and will receive approximately one third of the applicable income from Fujimoto. Fujimoto will also finance the development program needed for Emcitate in Japan, which will be clarified after discussions with the Pharmaceuticals and Medical Devices Agency (PMDA). As a future marketing authorisation holder (MAH) Fujimoto will be responsible for regulatory interactions with the PMDA.
As previously communicated, Egetis intends to commercialize Emcitate through its own organization in the US and Europe, and seek partnerships in other markets. This is the first such partnership to be announced, driven by the anticipated need for a local clinical trial in Japan prior to regulatory submissions. In addition to the ongoing clinical trials with Emcitate, around 190 patients in over 25 countries around the world, are already being treated with Emcitate as part of Egetis’ Managed Access programs. Furthermore, there is also a significant unmet medical need for treating MCT8 deficency patients in Japan. However, despite a significant number of patients diagnosed in Japan, none of these patients are currently treated with Emcitate. Iwayama et al. (Ref. 1) have reviewed the literature of MCT8 deficiency in Japan, and identified 36 already published cases. Kubota et al. (Ref. 2) in turn have conducted a nationwide survey of MCT8 deficiency and estimated there are over 60 cases with the disease in Japan, although this survey mainly asked questions to pediatric hospital facilities and did not survey adult departments.
Nicklas Westerholm, CEO of Egetis, commented: “We are delighted to enter this partnership with Fujimoto, to bring a treatment for MCT8 deficiency to patients in Japan, where there is a significant unmet medical need. Fujimoto is an ideal partner for the development, regulatory process and commercialization of Emcitate in Japan, with their long track record of bringing new medicines to patients in Japan.”
Mr. Masaya Fujimoto, President of Fujimoto, commented: “We have a long track record of bringing therapeutic medicines for CNS diseases, Blood diseases, and Orphan diseases to patients in Japan. We are pleased to have been granted the exclusive development and commercialization rights of Emcitate, an investigational drug candidate for MCT8 deficiency, from Egetis. Leveraging our previous experiences, we will continue to collaborate with Egetis and work diligently to obtain a marketing approval so that Emcitate can be used for the patients in Japan, as soon as possible.”
On October 9, 2023, the Company announced that it has submitted a marketing authorisation application for Emcitate for treatment of MCT8 deficiency to the European Medicines Agency (EMA). Emcitate has been granted Orphan Drug Designation by the EMA for MCT8 deficiency, and will, if approved by the European Commission be eligible for 10 years of market exclusivity within the EU.
As agreed with the US FDA, Egetis is conducting a randomized, placebo-controlled pivotal study (ReTRIACt) in 16 evaluable patients to verify the results on thyroid hormone T3 levels seen in previous clinical trials and publications. The study started recruiting in July this year. Topline results are expected during the first half of 2024 and Egetis intends to initiate the rolling submission of a new drug application (NDA) in the US for Emcitate in mid-2024 under the Fast-Track Designation granted by FDA.
References:
1. Iwayama, H. et al (2021) Regional Difference in Myelination in Monocarboxylate Transporter 8 Deficiency: Case Reports and Literature Review of Cases in Japan. Front. Neurol. 12:657820. doi.org/10.3389/fneur.2021.657820
2. Kubota, M. et al. (2022) A nationwide survey of monocarboxylate transporter 8 deficiency in Japan: Its incidence, clinical course, MRI and laboratory findings. Brain Development 44:699-705. doi.org/10.1016/j.braindev.2022.07.007
Link to www.clinicaltrials.com:
ReTRIACt
